Tarsus Pharmaceuticals, Inc.TARSNASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | 10.75% |
| Q3 2025 | 4.42% |
| Q2 2025 | 8.22% |
| Q1 2025 | -14.60% |
| Q4 2024 | 39.12% |
| Q3 2024 | -1.55% |
| Q2 2024 | 2.10% |
| Q1 2024 | -9.31% |
| Q4 2023 | 9.91% |
| Q3 2023 | -3.52% |
| Q2 2023 | 1.54% |
| Q1 2023 | 23.21% |
| Q4 2022 | -8.10% |
| Q3 2022 | 13.63% |
| Q2 2022 | -20.51% |
| Q1 2022 | 50.30% |
| Q4 2021 | -21.27% |
| Q3 2021 | 41.71% |
| Q2 2021 | -55.70% |
| Q1 2021 | 114.33% |
| Q4 2020 | -5.06% |
| Q3 2020 | 360.05% |
| Q2 2020 | 14.88% |
| Q1 2020 | 116.93% |
| Q4 2019 | 74.69% |
| Q3 2019 | 0.00% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |